DMAAR Drugs Made In America Acquisition Corp.: institutional ownership and insider trading
30 funds reported holding $1.53M of Drugs Made In America Acquisition Corp. in their latest 13F filings; in Q2 2026 funds net sold $350K, with 2 new positions and 9 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
DMAAR revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income $1.73M
- Quarter ended Mar 31, 2026: revenue n/a, net income $1.97M
- Quarter ended Dec 31, 2025: revenue n/a, net income $213K
- Quarter ended Sep 30, 2025: revenue n/a, net income $2.18M
Largest institutional holders of DMAAR
- Polar Asset Management Partners Inc. — $209K
- ATW SPAC MANAGEMENT LLC — $124K
- LINDEN ADVISORS LP — $97.8K
- MANGROVE PARTNERS IM, LLC — $93.5K
- TORONTO DOMINION BANK (TD, TDBCP) — $88.0K
- Hudson Bay Capital Management LP — $83.5K
- CLEAR STREET LLC — $80.8K
- Clear Street Group Inc. — $78.2K
- HIGHBRIDGE CAPITAL MANAGEMENT LLC — $77.3K
- RIVERNORTH CAPITAL MANAGEMENT, LLC — $62.7K
Recent DMAAR insider trades
- Feb 18, 2025: Stockwell Lynn bought 30,000 shares ($0)
- Feb 18, 2025: Drugs Made In America Acquisition LLC bought 30,000 shares ($0)
- Jan 29, 2025: Drugs Made In America Acquisition LLC sold 5,698,363 shares ($0)
- Jan 29, 2025: Drugs Made In America Acquisition LLC bought 400,000 shares ($0)
5%+ owners
- Drugs Made In America Acquisition LLC: 12.5% (Schedule 13D, filed Mar 3, 2025)
- KARPUS MANAGEMENT, INC.: 10.3% (Schedule 13G/A, filed Aug 14, 2026)
- Mizuho Financial Group, Inc.: 8.5% (Schedule 13G/A, filed Aug 13, 2026)
- Polar Asset Management Partners Inc.: 5.7% (Schedule 13G, filed May 15, 2025)
- Feis Equities LLC: 5.1% (Schedule 13G, filed Jun 26, 2026)